AMPH Q4 2023 Earnings — Amphastar Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMPHAmphastar Pharmaceuticals, Inc.

$894M

Q4 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$178M+31.9% YoY

Gross Profit

$96M54.0% margin

Operating Income

$54M30.3% margin

Net Income

$36M20.3% margin

EPS (Diluted)

$0.68

QoQ Revenue Growth

-1.4%

Cash Flow

Operating Cash Flow

$24M

Free Cash Flow

$14M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$1.5B

Total Liabilities

$873M

Stockholders' Equity

$639M

Cash & Equivalents

$144M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$178M	$135M	+31.9%
Gross Profit	$96M	$71M	+35.1%
Operating Income	$54M	$38M	+42.7%
Net Income	$36M	$34M	+6.6%

Revenue Segments

Product revenues, net

$441M95%

Other revenues

$22M5%

Geographic Segments

UNITED STATES

$175M98%

CHINA

$2M1%

FRANCE

$459,0000%